Ligand Pharmaceuticals (LGND) Operating Margin (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Operating Margin of 33.58% in Q1 2026, up 44.73% quarter-over-quarter from 23.2% in Q4 2025, and up 11347.0% year-over-year from N/an in Q1 2025.
Ligand Pharmaceuticals' Operating Margin history runs 17 years deep, the most recent figure standing at 33.58% for Q1 2026.
- In Q1 2026, Operating Margin rose 11347.0% year-over-year to 33.58%; the TTM figure through Mar 2026 stood at 34.46% (up 6852.0% YoY), while the FY2025 annual figure was 15.29%, up 2882.0% from the prior year.
- Operating Margin came in at 33.58% for Q1 2026 at Ligand Pharmaceuticals, up from 23.2% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 47.58% in Q3 2025 to a low of 79.89% in Q1 2025.
- A 5-year average of 0.92% and a median of 9.36% in 2023 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin slumped 10671 bps in 2022 and jumped 11347 bps in 2026, its largest moves.
- Ligand Pharmaceuticals' Operating Margin stood at 39.89% in 2022, then surged by 70 bps to 11.95% in 2023, then tumbled by 88 bps to 22.51% in 2024, then jumped by 203 bps to 23.2% in 2025, then surged by 45 bps to 33.58% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 33.58%, 23.2%, and 47.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn | 33.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.58% |
| Dec 31, 2025 | 23.20% |
| Sep 30, 2025 | 47.58% |
| Jun 30, 2025 | 17.73% |
| Mar 31, 2025 | -79.89% |
| Dec 31, 2024 | -22.51% |
| Sep 30, 2024 | 6.07% |
| Jun 30, 2024 | -45.99% |
| Mar 31, 2024 | 9.65% |
| Dec 31, 2023 | -11.95% |
| Sep 30, 2023 | 9.36% |
| Jun 30, 2023 | -7.52% |
| Mar 31, 2023 | 32.30% |
| Dec 31, 2022 | -39.89% |
| Sep 30, 2022 | 20.84% |
| Jun 30, 2022 | 17.28% |
| Mar 31, 2022 | 5.84% |
| Dec 31, 2021 | 66.82% |
| Sep 30, 2021 | 26.31% |
| Jun 30, 2021 | 58.00% |
| Mar 31, 2021 | 10.12% |
| Dec 31, 2020 | 32.67% |
| Sep 30, 2020 | 8.95% |
| Jun 30, 2020 | 17.14% |
| Mar 31, 2020 | 11.42% |
| Dec 31, 2019 | -37.70% |
| Sep 30, 2019 | -20.79% |
| Jun 30, 2019 | -16.53% |
| Mar 31, 2019 | 1,900.80% |
| Dec 31, 2018 | 55.63% |
| Sep 30, 2018 | 51.16% |
| Jun 30, 2018 | 77.93% |
| Mar 31, 2018 | 65.96% |
| Dec 31, 2017 | 47.58% |
| Sep 30, 2017 | 36.12% |
| Jun 30, 2017 | 14.45% |
| Mar 31, 2017 | 18.19% |
| Dec 31, 2016 | 50.69% |
| Sep 30, 2016 | 25.28% |
| Jun 30, 2016 | 20.33% |
| Mar 31, 2016 | 50.92% |
| Dec 31, 2015 | 51.98% |
| Sep 30, 2015 | 48.57% |
| Jun 30, 2015 | 23.70% |
| Mar 31, 2015 | 22.94% |
| Dec 31, 2014 | 41.90% |
| Sep 30, 2014 | 23.59% |
| Jun 30, 2014 | 12.80% |
| Mar 31, 2014 | 31.96% |
| Dec 31, 2013 | 43.60% |
| Sep 30, 2013 | 23.61% |
| Jun 30, 2013 | 15.80% |
| Mar 31, 2013 | 33.75% |
| Dec 31, 2012 | 31.34% |
| Sep 30, 2012 | -22.35% |
| Jun 30, 2012 | -31.61% |
| Mar 31, 2012 | -14.89% |
| Dec 31, 2011 | 36.04% |
| Sep 30, 2011 | -56.59% |
| Jun 30, 2011 | -10.85% |
| Mar 31, 2011 | -38.06% |
| Dec 31, 2010 | -151.32% |
| Sep 30, 2010 | -200.91% |